Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Devitt

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Cognitive Science|April 25, 2018
The Reference of Proper Names: Testing Usage and IntuitionsMichael Devitt, Nicolas Porot
Cognitive Science|January 26, 2025
The New-Meaning Objection: A Reply to Nicolò D'AgrumaMichael Devitt, Nicolas Porot
Cognitive Science|May 21, 2021
Testing the Reference of Biological Kind TermsMichael Devitt, Brian C Porter
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 11, 2024
Clinical Management of Advanced Prostate Cancer: Where Does Radiopharmaceutical Therapy Fit in the Treatment Algorithm?Paul Viscuse, Michael Devitt, Robert Dreicer
Clinical Genitourinary Cancer|November 28, 2024
Impact of Renin-Angiotensin System Inhibitors on Response to PD1/L1 Inhibitors in Patients With Metastatic Renal Cell CarcinomaKathryn Fortune, Soham Ali, Jack Masur, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 6, 2018
Risk of Major Bleeding with IbrutinibJoseph Mock, Paul R Kunk, Surabhi Palkimas, et al.
Investigational New Drugs|September 4, 2025
A phase 1b/2 study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer and no mutations in DNA damage response genesKaren A Autio, Christos E Kyriakopoulos, Paul Palyca, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2022
EphrinB2 Inhibition and Pembrolizumab in Metastatic Urothelial CarcinomaSarmad Sadeghi, David Quinn, Tanya Dorff, et al.
Cancer Research|June 4, 2024
Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant CancersPatricia J Keller, Elizabeth J Adams, Rentian Wu, et al.
Cancer|December 13, 2019
Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitorsAli Raza Khaki, Ang Li, Leonidas N Diamantopoulos, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Cognitive Science|April 25, 2018
The Reference of Proper Names: Testing Usage and IntuitionsMichael Devitt, Nicolas Porot
Cognitive Science|January 26, 2025
The New-Meaning Objection: A Reply to Nicolò D'AgrumaMichael Devitt, Nicolas Porot
Cognitive Science|May 21, 2021
Testing the Reference of Biological Kind TermsMichael Devitt, Brian C Porter
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 11, 2024
Clinical Management of Advanced Prostate Cancer: Where Does Radiopharmaceutical Therapy Fit in the Treatment Algorithm?Paul Viscuse, Michael Devitt, Robert Dreicer
Clinical Genitourinary Cancer|November 28, 2024
Impact of Renin-Angiotensin System Inhibitors on Response to PD1/L1 Inhibitors in Patients With Metastatic Renal Cell CarcinomaKathryn Fortune, Soham Ali, Jack Masur, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 6, 2018
Risk of Major Bleeding with IbrutinibJoseph Mock, Paul R Kunk, Surabhi Palkimas, et al.
Investigational New Drugs|September 4, 2025
A phase 1b/2 study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer and no mutations in DNA damage response genesKaren A Autio, Christos E Kyriakopoulos, Paul Palyca, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2022
EphrinB2 Inhibition and Pembrolizumab in Metastatic Urothelial CarcinomaSarmad Sadeghi, David Quinn, Tanya Dorff, et al.
Cancer Research|June 4, 2024
Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant CancersPatricia J Keller, Elizabeth J Adams, Rentian Wu, et al.
Cancer|December 13, 2019
Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitorsAli Raza Khaki, Ang Li, Leonidas N Diamantopoulos, et al.
Pageof 2